2025
Voxel-Wise Map of Intracerebral Hemorrhage Locations Associated With Worse Outcomes
Karam G, Chen M, Zeevi D, Harms B, Berson E, Torres-Lopez V, Rivier C, Malhotra A, Qureshi A, Falcone G, Sheth K, Payabvash S. Voxel-Wise Map of Intracerebral Hemorrhage Locations Associated With Worse Outcomes. Stroke 2025, 56: 868-877. PMID: 40052269, DOI: 10.1161/strokeaha.124.048453.Peer-Reviewed Original ResearchConceptsImpact of intracerebral hemorrhageAssociated with worse outcomesClinical risk factorsVoxel-wise mapsMapping of brain regionsBaseline hematomaVoxel-wise analysisHematoma volumeICH locationBrain regionsValidation cohortWorse outcomesPresence of intraventricular hemorrhageRisk factorsBaseline hematoma volumeModified Rankin Scale scorePoor scan qualityMulticenter clinical trialRankin Scale scoreDeep white matterLow-risk categoryComprehensive stroke centerIntraventricular hemorrhageConsecutive patientsPatient ageChapter 48 Multicenter considerations
Passarelli R, Sterling J, Singer E, Kim I. Chapter 48 Multicenter considerations. 2025, 245-248. DOI: 10.1016/b978-0-323-90186-4.00029-8.Peer-Reviewed Original Research
2024
Variability in temperature control practices amongst the Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP) trial
Beekman R, Perman S, Nguyen C, Kline P, Clevenger R, Yeatts S, Ramakrishnan R, Geocadin R, Silbergleit R, Meurer W, Gilmore E. Variability in temperature control practices amongst the Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP) trial. Resuscitation 2024, 203: 110397. PMID: 39278393, PMCID: PMC11466710, DOI: 10.1016/j.resuscitation.2024.110397.Peer-Reviewed Original Research
2023
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
Kurz S, Zan E, Cordova C, Troxel A, Barbaro M, Silverman J, Snuderl M, Zagzag D, Kondziolka D, Golfinos J, Chi A, Sulman E. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clinical Cancer Research 2023, 30: 680-686. PMID: 38048045, DOI: 10.1158/1078-0432.ccr-23-2533.Peer-Reviewed Original ResearchConceptsProgression-free survivalSomatostatin receptor type 2PFS-6Stable diseaseOverall survivalIntracranial meningiomasSingle-arm phase II clinical studyMedian progression-free survivalPhase II clinical studyImaging biomarkersCourse of radiationReceptor type 2Multicenter clinical trialMacdonald criteriaMedian OSRadiographic responseProgressive meningiomasTumor measurementsTumor resectionMedian agePrimary endpointRadiotherapeutic interventionSecondary endpointsMedical therapyAdult patients1747. Clinical Spectrum of a Large Multi-State U.S. Cohort of Parechovirus Infection in Neonates and Young Infants
Evans A, Filkins L, Custodio H, Daniels E, Kao C, Richardson K, Carrillo-Marquez M, Borré C, Oliveira C, Espinosa C, Bocchini J, Mandelia Y, Mazade M, Santos R, Carr S, Selvarangan R, Kimberlin D. 1747. Clinical Spectrum of a Large Multi-State U.S. Cohort of Parechovirus Infection in Neonates and Young Infants. Open Forum Infectious Diseases 2023, 10: ofad500.1578. PMCID: PMC10678563, DOI: 10.1093/ofid/ofad500.1578.Peer-Reviewed Original ResearchUniversity of Mississippi Medical CenterMulticenter clinical trialHPeV infectionStudy discontinuationClinical trialsYoung infantsMedical CenterIndustry-sponsored clinical trialsSevere HPeV infectionsMedian hospitalization durationBody fluid specimensParechovirus infectionMedian ageU.S. outbreakPediatric patientsClinical spectrumHospitalization durationFluid specimensHuman parechovirusIRB approvalReport mortalityViral testingBiochemical markersBirth historyInterim analysisEffects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy
Heinze C, Burgess K, Barber L, Rassnick K, Post G, Segaloff R, Bayle J. Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy. Veterinary And Comparative Oncology 2023, 22: 2-11. PMID: 37933436, PMCID: PMC11115191, DOI: 10.1111/vco.12940.Peer-Reviewed Original ResearchQuality of lifeAdverse eventsFecal scoreGastrointestinal adverse eventsC-reactive proteinClient-owned dogsMulticenter clinical trialChemoattractant protein-1Mast cell tumorsFrequency of signsSignificant differencesCancer treatment optionsImpact of dietTest dietsQOL parametersCare chemotherapyLaboratory parametersPrimary outcomeOncology patientsFatty acidsLarge trialsMulticentric lymphomaQOL improvementTreatment optionsCell tumorsOUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
Puthenpura V, Bona K, Cooney T, Coven S, Davidson T, Fouladi M, Kline C, Leary S, Mueller S, Green A, Marks A. OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES. Neuro-Oncology 2023, 25: i37-i37. PMCID: PMC10260067, DOI: 10.1093/neuonc/noad073.145.Peer-Reviewed Original ResearchNeuro-oncology patientsMulticenter clinical trialClinical trialsSocial determinantsSocioeconomic statusClinical Trials ConsortiumLong-term complicationsAYA cancer patientsAdverse social determinantsSocioeconomic status dataAdverse SDOHSurvival disparitiesMultidisciplinary careTherapy adherenceToxicity incidenceCancer patientsTrial therapyPersonal socioeconomic statusOutcome disparitiesTrial designSDOHPatientsHealth equityHealth data collectionTrialsEvaluating the feasibility of a multicenter teleneonatology clinical effectiveness trial
Fang J, Umoren R, Whyte H, Limjoco J, Makkar A, Behl S, Lo M, White L, Culjat M, Taylor J, Kathuria S, Webb M, Schad T, Shafranski S, Yankanah R, Herrin J, Demaerschalk B. Evaluating the feasibility of a multicenter teleneonatology clinical effectiveness trial. Pediatric Research 2023, 94: 1555-1561. PMID: 37208433, DOI: 10.1038/s41390-023-02659-2.Peer-Reviewed Original ResearchConceptsClinical effectiveness trialCommunity hospitalEffectiveness trialPilot studyRisk neonatesClinical trialsHealth outcomesNeonatal intensive care unitProspective multicenter trialIntensive care unitMulticenter clinical trialFeasibility scoreMulticenter trialPrimary outcomeCare unitEarly health outcomesTrial protocolMain trialTelemedicine consultationsHospitalTrialsNeonatesOutcomesResearch ConsortiumScoresAKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.Peer-Reviewed Original ResearchEndocrine therapyProgressive diseaseCDK4/6 inhibitionImmune cellsTumor epitheliumOpen-label multicenter clinical trialMetastatic breast cancer patientsPI3K/AKT/mTOR activationFirst-line treatmentMetastatic breast cancerBreast cancer patientsAkt/mTOR activationMulticenter clinical trialAkt/mTORMBC patientsCancer patientsPredictive markerClinical trialsDisease progressionBreast cancerTreatment selectionTissue biopsiesPatientsNumber of FDAMTOR activationInpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial
Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.Peer-Reviewed Original ResearchConceptsOpioid use disorderFull agonist opioidsAgonist opioidsHospital dischargeCase seriesSurgical interventionUse disordersCurrent opioid use disorderInfectious disease physiciansLow-dose strategyMulticenter clinical trialPotential surgical interventionLife-threatening infectionsCOMMIT trialComplex hospitalizationsDepot buprenorphineOpioid relapseUnderused medicationsOpioid withdrawalSublingual buprenorphineBuprenorphine dosesDisease physiciansConcurrent painClinical trialsConcurrent infection
2022
Magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremor: 5-year follow-up results
Cosgrove GR, Lipsman N, Lozano AM, Chang JW, Halpern C, Ghanouni P, Eisenberg H, Fishman P, Taira T, Schwartz ML, McDannold N, Hayes M, Ro S, Shah B, Gwinn R, Santini VE, Hynynen K, Elias WJ. Magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremor: 5-year follow-up results. Journal Of Neurosurgery 2022, 138: 2022.6.jns212483. PMID: 35932269, PMCID: PMC10193464, DOI: 10.3171/2022.6.jns212483.Peer-Reviewed Original ResearchConceptsFunctional disability scoreAdverse eventsFocused ultrasound thalamotomyQuality of lifeDisability scoresMotor scoresUltrasound thalamotomyMagnetic resonance imaging-guided focused ultrasound thalamotomyEssential tremorMedication-refractory essential tremorNew adverse eventsCohort of patientsQUEST scoresMulticenter clinical trialClinical trial registrationEssential Tremor QuestionnaireLong-term safetyClinical rating scalesRespective time pointsTremor improvementTRIAL REGISTRATIONClinical trialsTremor scorePostural tremorLife measuresSafety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial
Sherr JL, Bode BW, Forlenza GP, Laffel LM, Schoelwer MJ, Buckingham BA, Criego AB, DeSalvo DJ, MacLeish SA, Hansen DW, Ly TT, Sherr J, Weyman K, Tichy E, VanName M, Brei M, Zgorski M, Steffen A, Carria L, Bode B, Busby A, Forlenza G, Wadwa R, Slover R, Cobry E, Messer L, Laffel L, Isganaitis E, Ambler-Osborn L, Freiner E, Turcotte C, Volkening L, Schoelwer M, Brown S, Krauthause K, Emory E, Oliveri M, Buckingham B, Ekhlaspour L, Kingman R, Criego A, Schwartz B, Gandrud L, Grieme A, Hyatt J, DeSalvo D, McKay S, DeLaO K, Villegas C, MacLeish S, Wood J, Kaminski B, Casey T, Campbell W, Behm K, Adams R, Hansen D, Stone S, Bzdick S, Bulger J, Agostini L, Doolittle S, Kivilaid K, Kleve K, Ly T, Dumais B, Vienneau T, Huyett L, Lee J, O’Connor J, Benjamin E. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care 2022, 45: 1907-1910. PMID: 35678724, PMCID: PMC9346983, DOI: 10.2337/dc21-2359.Peer-Reviewed Original ResearchConceptsInsulin delivery systemsSingle-arm studyLong-term complicationsMulticenter clinical trialType 1 diabetesSensor glucose levelsYoung childrenBaseline data collectionReduced hypoglycemiaDiabetic ketoacidosisGlycemic targetsUsual therapyGlycemic measuresSevere hypoglycemiaDelivery systemStudy endGlycemic outcomesClinical trialsGlucose levelsType 1HypoglycemiaInvestigational systemDlChildrenStudy phaseSelective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial
Chan S, Chotipanich C, Choo S, Kwang S, Mo F, Worakitsitisatorn A, Tai D, Sundar R, Ng D, Loke K, Li L, Ng K, Peng Y, Yu S. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. Liver Cancer 2022, 11: 451-459. PMID: 36158588, PMCID: PMC9485918, DOI: 10.1159/000525489.Peer-Reviewed Original ResearchUnresectable intrahepatic cholangiocarcinomaProgression-free survivalSelective internal radiation therapyInternal radiation therapyIntrahepatic cholangiocarcinomaMedian OSRadiation therapyOverall survivalClinical trialsMedian cycle of chemotherapyMedian progression-free survivalResin yttrium-90 microspheresYttrium-90 resin microspheresTreatment-related adverse eventsIntent-to-treat populationResponse rateDisease control rateResponse Evaluation CriteriaYttrium-90 microspheresCycles of chemotherapyWithdrawal of consentMulticenter clinical trialInvestigator-initiated clinical trialStandard gemcitabineStandard chemotherapy
2021
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
Hutchison R, Evans K, Fox T, Yang M, Barakos J, Bedell B, Cedarbaum J, Brys M, Siderowf A, Lang A. Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial. BMC Neurology 2021, 21: 459. PMID: 34814867, PMCID: PMC8609885, DOI: 10.1186/s12883-021-02470-8.Peer-Reviewed Original ResearchConceptsDAT-SPECTParkinson's diseaseClinical trialsDisease trialsPhase 2 trialDopaminergic nerve terminalsEarly Parkinson's diseaseDisease-modifying therapiesIdiopathic Parkinson's diseaseMulticenter clinical trialParkinson's disease trialStudy design aspectsSingle photon emissionStages of progressionDegenerative parkinsonismEnrichment biomarkerResultsIn totalClinical assessmentNerve terminalsBlinded neuroradiologistsClinical diagnosisDopamine transporterMonoclonal antibodiesCentral laboratoryTrialsLong-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertensionEffect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease
Bernstein R, Kamel H, Granger C, Piccini J, Sethi P, Katz J, Vives C, Ziegler P, Franco N, Schwamm L, Acosta I, Jamnadas P, Manda S, Alimohammad R, Arias V, Tempro K, Ward K, Asi K, Choudhuri I, Guerrero W, Kalia J, Niazi I, Sajjad R, Thavapalan V, Assar M, Banchs J, Black J, Cheung P, Donsky A, Graybeal D, Hasan R, Mir O, Nguyen C, Olsovsky G, Rasmussen J, Hasabnis S, Reeves R, Rowley C, Sharma J, Smith M, Bonyak K, Sackett M, Allred J, Sethi P, Jung R, Lynch J, Rowe S, Dash S, Glotzer T, Jamal S, Radoslovich G, Shukla G, Zimmerman J, Hussein H, Zhu D, Krueger K, Ostrander M, Ramirez D, Shultz J, Simonson J, Cucchiara B, Deo R, Frankel D, Jia J, Kasner S, Luciano J, Messe S, Mullen M, Santangeli P, Schaller R, Yuan Q, Bledsoe D, Cajavilca C, Chiu D, Gadhia R, Grimes M, Katz L, Moye S, Rami T, Thomas A, Volpi J, Al Balushi A, Boyd C, Choudry S, Dhamoon M, Dukkipati S, Goltz D, Hao Q, Horowitz D, Kaur G, Koruth J, Kurian C, Langan M, Matos Diaz I, Miller M, Reddy V, Sheinart K, Stein L, Tansy A, Tuhrim S, Weinberger J, Whang W, Cross J, Kreger H, Saltzman M, Zide K, Bansal S, Bernabei M, Flaster M, Barrett C, Etherton M, Heist E, Lubitz S, Regenhardt R, Sharma R, Silverman S, Sloane K, Viswanathan A, Doshi A, Logan W, Malik M, Rempe D, Arora R, Beldner S, Epstein L, Ismail H, Jadonath R, Katz J, Libman R, Moussavi M, Patel A, Patel A, Willner J, Wright P, Caprio F, Kim S, Mendelson S, Passman R, Ruff I, Alsorogi M, Chaudhary G, Morris K, Mullins S, Talpur N, Thomas K, Chancellor B, Chinitz L, Culpepper A, Fara M, Ishida K, Lillemoe K, Lord A, Torres J, Zhang C, Abi-Samra F, Bernard M, Carter J, Chokhawala H, Downey A, Khatib S, Morin D, Polin G, Rogers P, Vidal G, Zweifler R, Belt G, Felberg R, Furer S, Hanna J, McCall-Brown A, Seeger S, Reddy R, Skalabrin E, Soik D, Wilder M, Kearney M, LaFranchise E, Parker B, Pickett R, Bonaguidi H, Gibson D, Kalafut M, Mattera B, Olson N, Parker M, Rogers J, Uddin P, Chang C, Graner S, Kipta J, Salem R, Singh D, Al-Awwad A, Beaver B, Chaudhary S, Clayton S, Delpirou Nouh C, Garabelli P, Gordon D, Pakala A, Ray B, Saucedo S, Sidorov E, Stavrakis S, Ching M, Deline C, Hourihane J, Kandel A, Kim C, Magun R, Mowla A, Sawyer R, Switzer D, Badhwar N, Lee R, Meisel K, Smith W, Alkahalifah M, Aroor S, Asdaghi N, Bhatt N, Del Brutto V, Dillon G, Gadient P, Koch S, Lambrakos L, Malik A, Marulanda-Londono E, Memon Z, Mendoza I, Mitrani R, Ortiz G, Ramano J, Sur N, Torres L, Daniels J, Johnson M, Magadan A, Shang T, Mcclelland N, Merriam T, Neisen K. Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease. JAMA 2021, 325: 2169-2177. PMID: 34061145, PMCID: PMC8170544, DOI: 10.1001/jama.2021.6470.Peer-Reviewed Original ResearchConceptsSmall vessel diseaseAtrial fibrillationUsual careCardiac monitoringIndex strokeICM groupControl groupAdditional stroke risk factorsProcedure-related adverse eventsAF incidence ratesMore atrial fibrillationCHA2DS2-VASc scorePrimary end pointStroke risk factorsIncident atrial fibrillationMulticenter clinical trialAF detectionContinuous cardiac monitoringLong-term cardiac monitoringEligible patientsAdverse eventsIschemic strokeHolter monitoringRisk factorsClinical trials
2020
Spectral editing in 1H magnetic resonance spectroscopy: Experts' consensus recommendations
Choi I, Andronesi O, Barker P, Bogner W, Edden R, Kaiser L, Lee P, Marjańska M, Terpstra M, de Graaf R. Spectral editing in 1H magnetic resonance spectroscopy: Experts' consensus recommendations. NMR In Biomedicine 2020, 34: e4411. PMID: 32946145, PMCID: PMC8557623, DOI: 10.1002/nbm.4411.Peer-Reviewed Original ResearchConceptsSpectral editingIn vivo<sup>1</sup>H MRS, paMulticenter clinical trialSpectral fittingExpert consensus recommendationsD-2-hydroxyglutarateJ-couplingG-aminobutyric acidH-MRSFrequency driftClinical trialsSignal overlapConsensus recommendationsMagnetic resonance spectroscopyMetabolite signalsResonance spectroscopyResonanceExpert recommendationsSequence parameters
2019
Pioglitazone Therapy in Patients With Stroke and Prediabetes
Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN. Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology 2019, 76: 526-535. PMID: 30734043, PMCID: PMC6515584, DOI: 10.1001/jamaneurol.2019.0079.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHeart FailureHospitalizationHumansHypoglycemic AgentsInsulin ResistanceMaleMedication AdherenceMiddle AgedMyocardial InfarctionPioglitazonePrediabetic StateProportional Hazards ModelsRecurrenceSecondary PreventionStrokeConceptsAcute coronary syndromeStroke/myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeHeart failureIRIS trialInsulin resistanceGood adherenceIschemic attackRecurrent strokeHazard ratioClinical trialsStroke/transient ischemic attackRandomized multicenter clinical trialAmerican Diabetes Association criteriaInsulin Resistance InterventionHemoglobin A1c levelsEffect of pioglitazoneInsulin-sensitizing agentsMulticenter clinical trialPlasma glucose levelsSerious bone fracturesPlacebo cohortPrior strokeAssociation between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population
Trussell JC, Coward RM, Santoro N, Stetter C, Kunselman A, Diamond MP, Hansen KR, Krawetz SA, Legro RS, Heisenleder D, Smith J, Steiner A, Wild R, Casson P, Coutifaris C, Alvero RR, Robinson RB, Christman G, Patrizio P, Zhang H, Lindgren MC, Network R. Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population. Fertility And Sterility 2019, 111: 1129-1134. PMID: 30982604, PMCID: PMC6557574, DOI: 10.1016/j.fertnstert.2019.01.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersDown-RegulationFemaleFertilityHumansInfertility, MaleInsemination, Artificial, HomologousLive BirthMaleMulticenter Studies as TopicPregnancyPregnancy RateRandomized Controlled Trials as TopicRisk FactorsSperm CountSperm MotilitySpermatogenesisTestosteroneTreatment OutcomeConceptsUnexplained infertilityLow TTMale partnersLive birthsSemen parametersSecondary analysisMultiple Intrauterine GestationsLive birth rateBody mass indexMulticenter clinical trialAbnormal sperm morphologyOvarian stimulationIntrauterine gestationPregnancy outcomesMass indexInfertility clinicClinical trialsMAIN OUTCOMETotal motile spermSemen analysisAbnormal spermatogenesisInfertilityLogistic regressionSperm concentrationSemen volume
2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Godellas C, Chen M, Kalinsky K, Hibshoosh H, Killelea B, Sanft T, Hirst G, Asare S, Matthews J, Perlmutter J, Esserman L, and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer 2018, 4: 26. PMID: 30131975, PMCID: PMC6098077, DOI: 10.1038/s41523-018-0074-6.Peer-Reviewed Original ResearchAxillary lymph node dissectionLymph node dissectionClinical trialsNeoadjuvant chemotherapyNode dissectionPositive diseaseDrug therapy trialsI-SPY2 trialManagement of axillaBreast cancer clinical trialsNode-positive diseaseProspective clinical trialsMulticenter clinical trialAssessment of responseClinical trial dataCancer clinical trialsNeoadjuvant settingPrimary endpointNodal involvementSurgical resectionSurgical managementProper stagingResidual diseaseSurgical standardAxilla
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply